<DOC>
	<DOCNO>NCT00974324</DOCNO>
	<brief_summary>The role angiogenesis less clear lymphoma solid tumor , part relate heterogeneity disease technical issue . In addition vascular endothelial growth factor ( VEGF ) effect angiogenesis integrity tumor vasculature , autocrine VEGF-receptor ( VEGF-R ) -mediated signaling may play role lymphoma . Microvessel density , measure angiogenesis , high peripheral T-cell lymphoma ( PTCL ) , follow diffuse large B-cell ( DLBCL ) intra-follicular follicular lymphoma ( FL ) .</brief_summary>
	<brief_title>Endostar Combined With CHOP Regimen First Line Chemotherapy Peripheral T Cell Lymphoma</brief_title>
	<detailed_description>To investigate efficacy safety endostar combine CHOP regimen first line treatment peripheral T cell lymphoma.The second subject clarify association expression VEGF prognosis peripheral T cell lymphoma , unspecified ( PTCL-U ) angioimmunoblastic T-cellLymphoma ( AILT ) .Methods 15 case PTCL enrol study.Immunohistochemical staining perform EnVision method use antibody VEGF .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>Disease Characteristics : Diagnosis peripheral Tcell : Any stage disease allow At least 1 objective measurable disease parameter No anaplastic lymphoma kinase ( ALK ) positive Tcell large cell lymphoma ALKnegative Tcell large cell lymphoma allow No cutaneous Tcell lymphoma No sezary syndrome No NK/T cell lymphoma No history current radiographic evidence CNS metastasis , include previously treat , resect , asymptomatic brain lesion leptomeningeal involvement Patient Characteristics : Age : 18 75 year Performance status : ECOG 02 Life expectancy : No less 12 week Hematopoietic : Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobulin ≥ 80*10^12/L Platelet count ≥ 100,000/mm^3 No evidence bleed diathesis coagulopathy Hepatic : Bilirubin ≤ 1.5 mg/dL AST ≤ 2.5 time ULN PT , INR , PTT ≤ 1.5 time normal Renal : Creatinine ≤ 1.5 time normal Cardiovascular : No cerebrovascular accident within past 6 month No myocardial infarction within past 6 month No unstable angina within past 6 month No New York Heart Association class IIIV congestive heart failure No uncontrolled hypertension ( i.e. , systolic blood pressure [ BP ] &gt; 150 mm Hg diastolic BP &gt; 100 mm Hg ) No clinically significant cardiovascular peripheral vascular disease LVEF normal Other : Not pregnant nursing Fertile patient must use effective contraception No history active seizures No nonhealing ulcer ( unless involve lymphoma ) No active infection require parenteral antibiotic No know HIV positivity No active malignancy within past 6 month except carcinoma situ cervix basal cell carcinoma skin PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy allow Surgery : More 4 week since prior major invasive surgery open biopsy At least 7 day since prior minor surgery No concurrent major surgery Prior treatment include chemotherapy radiotherapy With follow risk factor : Uncontrolled severe cardiovascular disease ( e.g. , myocardial infarction within past 6 month , congestive heart failure treat medication , uncontrolled hypertension ) Pregnant nurse Other currently active malignancy except nonmelanoma skin cancer Uncontrolled severe bleeding , diarrhea , intestinal obstruction Hypersensitivity albumen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>peripheral T cell lymphoma</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>anti-angiogeneses</keyword>
</DOC>